Louisiana State University

Louisiana State University Health Sciences Center-Shreveport, a division of Louisiana State University operating as a state government educational medical institution, serves as a prime recipient and prime contractor delivering medical education, clinical neurosurgery services, and biomedical research to federal agencies on a full-and-open basis, with substantial grant portfolio spanning NIH intramural research programs and VA healthcare delivery.

The institution operates as a public academic medical center located in Shreveport, Louisiana, delivering concrete capabilities in tuition and fees support for military medical personnel training, affiliate neurosurgery services for veterans, and federally funded basic and translational biomedical research. Recent activity shows 25 awards in 2026 and 33 in 2025, spanning prime contracts, grant awards, and subcontract positions across 623 total federal transactions tracked in the source data, with combined potential value of $29.6 million and combined obligated dollars of $462.7 million.

Customer concentration centers on the Department of Veterans Affairs Veterans Integrated Service Network 16, which anchors the largest potential-value share with 37 awards worth $19.2 million for affiliate neurosurgery services delivered through a single-award indefinite-delivery contract (ceiling $600,000, completion March 31, 2027) and successive delivery orders. The Department of the Navy Bureau of Medicine and Surgery places 69 awards totaling $3.2 million in potential value, predominantly for tuition and fees supporting Navy medical personnel education. The National Institutes of Health directs 67 awards across multiple institutes—National Heart Lung and Blood Institute (35 awards), National Cancer Institute (18 awards), National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, and others—for biomedical research in cardiovascular disease, cancer biology, infectious disease, and neuroscience. The top five customer agencies represent 36 percent of award count. Research grant work runs concurrent with contract delivery, with recent NIH awards including $732.7 million for cellular reductive state in atherosclerotic disease resolution (NHBLI, July 2026), $513.4 million for eosinophil-mediated persistence in Bordetella infections (NIAID, June 2026), $416 thousand for engineered oncolytic HSV-1 immunotherapy (NCI, July 2025), and $7.5 million for the EPSCOR CREST Phase I Center for Post-Transcriptional Regulation (NSF, October 2025).

Prime contract work anchors to five primary parent vehicles: Indefinite Delivery Contract N0014098G2471 (27 task orders, $719 thousand), Indefinite Delivery Contract V502P2516 (26 task orders, $380 thousand), Indefinite Delivery Contract V667P1962 (18 task orders, $1.3 million), and two additional VA indefinite-delivery contracts. Place of performance is Shreveport, Louisiana, with administrative oversight from the institution's medical center divisions. NAICS framing is split between General Medical and Surgical Hospitals (179 awards), Colleges, Universities, and Professional Schools (96 awards), and Research and Development in Biotechnology (7 awards). Federal grants operate under CFDA programs including 93.837 (Cardiovascular Diseases Research), 93.855 (Allergy and Infectious Diseases Research), 93.853 (Neurosciences and Neurological Disorders), 93.859 (Biomedical Research and Research Training), 93.273 (Alcohol Research), 93.121 (Oral Diseases and Disorders Research), 47.076 (STEM Education), and 93.262 (Occupational Safety and Health).

The institution serves as sub-recipient on multiple grants from prime grantees including Pennington Biomedical Research Center (Health Literacy Core for Louisiana CaTS Center), Louisiana Department of Health (Nurse Family Partnership, sickle cell disease patient services), Dana-Farber Cancer Institute (Louisiana Tumor Registry administration for AYA cancer research), and Washington University (tumor angiogenesis and immunity research). Recent grant sub-awards carry performance roles in participant recruitment, outcome assessment, and collaborative scientific analysis across multi-site research initiatives. As a prime recipient, the institution acts independently on research proposals addressing federal priorities in cardiovascular health, infection control, neurodegenerative disease, cancer prevention, and occupational health.

Activity trajectory shows 17 awards in 2022, growing to 34 in 2024 and declining slightly to 25 by September 2026. Thirty-two awards (combined potential value $654 thousand) face ultimate completion within the next twenty-four months, creating recompete exposure principally on renewal of educational delivery orders and neurosurgery service contracts with the VA and Navy Bureau of Medicine and Surgery. The institution competes on contracts on a full-and-open basis without socioeconomic set-asides; all contracts cited carry "No Set-Aside Used" designation.